MentalHealthDaily

Evening Chronotype & Lower Efficacy of SSRI Antidepressants (2024 Study)

by GLOOM

Recent research in the Australian Genetics of Depression Study reveals a fascinating connection between an individual’s chronotype and the efficacy of antidepressants. A study, focusing on selective-serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), suggests that evening chronotypes may experience poorer responses to these medications. Highlights: Chronotype Impact: Individuals with an evening chronotype reported …

Comparison of Brexipiprazole vs. Aripiprazole for Treatment-Resistant Depression (2024 Study)

by GLOOM

Antidepressant-resistant major depressive disorder (AR-MDD) poses significant challenges in psychiatric treatment. Antipsychotics like aripiprazole (ARI) and brexpiprazole (BRE) have emerged as effective adjunct therapies that may be more tolerable than older antipsychotics. Highlights: Both Brexipiprazole and Aripiprazole demonstrated better efficacy than placebo in treating AR-MDD in Japanese patients. Brexipiprazole showed a higher discontinuation rate due …

Low Dose LSD for Depression Treatment: Preliminary Efficacy (2023 Study)

by GLOOM

Recent research exploring the use of low doses of LSD (Lysergic acid diethylamide) in treating depression marks a significant shift in the psychiatric landscape. This innovative approach seeks to understand and harness the potential therapeutic benefits of psychedelics, which were once stigmatized and largely overlooked in clinical settings. Highlights: Study Design: The research employed a …

Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) for Rapid Treatment of Suicidal Depression (2023 Study)

by GLOOM

Major depressive disorder (MDD) is a critical public health issue, particularly due to the high risk of suicide associated with it. Traditional treatments often take weeks to show effects and sometimes increase suicide risk in the early phases of therapy. However, a new approach, the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), is showing promise in …

Psychedelics for Depression: Targeting the 5-HT2A Receptor & Beyond (2023 Study)

by GLOOM

The quest for effective treatments for Major Depressive Disorder (MDD) has taken a revolutionary turn with the exploration of psychedelic compounds. Recent research has evaluated the potential of substances like psilocybin and lisuride, offering new hope for patients unresponsive to traditional antidepressants. Highlights: Traditional Limitations: Standard antidepressants often fail to provide relief for 30% of …

Vortioxetine Efficacy for Major Depression & Comorbid Anxiety (2023 Study)

by GLOOM

The RELIEVE study provides pivotal insights into the effectiveness of vortioxetine in treating patients with Major Depressive Disorder (MDD) co-morbid with Generalized Anxiety Disorder (GAD). A subgroup analysis of the observational study highlights significant improvements in patient functioning, depression severity, cognitive symptoms, and quality of life. The findings underscore vortioxetine’s potential as a beneficial treatment …

Quetiapine Dosing for Depression Optimized with XGBoost Algorithm (2024 Study)

by GLOOM

Depression is a globally pervasive mental illness that often requires complex treatment strategies. One such strategy involves the use of Quetiapine, an antipsychotic medication, as an augmentation to antidepressants. However, determining the optimal dose of Quetiapine is challenging due to individual variability. A recent study utilizes machine learning techniques to develop a predictive model for …